Wockhardt Ltd.

Oxurion Receives Transparency Notifications Leuven, BELGIUM, Boston, MA, US – February 10, 2022 – 7.30 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on February 9, 2023 from Negma Group Ltd. indicating that as of February 3, 2023, it held 12,528,163 shares of the then outstanding 466,875,130 shares, and therefore crossed below the threshold (3%) by virtue of disposal of voting securities. See Annex 1 Oxurion received a transparency notification on February 8, 2023 from Negma Group Ltd. indicating that as of February 1, 2023, it held 17,693,115 shares of the then outstanding 466,875,130 shares, and therefore crossed below the threshold (5%) by virtue of disposal of voting securities. See Annex 2 In addition, Oxurion informs the markets that it has updated the Transparency Notifications section of its investor relations website (https://ir.oxurion.com/shareholder-information/transparency-notifications) to incorporate additional transparency notifications from Negma, Thomas M. Clay/Epacria Capital Partners LLC and Philippe Vlerick/Bareldam SA disclosing their positions having crossed below the threshold (3%) by virtue of the issuance of new voting securities in late 2022. About Oxurion Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com. Important information about forward-looking statements Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws. For further information please contact: Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13 10 " tom.graney@oxurion.com Michael DillenChief Business OfficerTel: +32 16 75 13 10michael.dillen@oxurion.com USConway CommunicationsMary T. Conwaymtconway@conwaycommsir.com ICR WestwickeChristopher BrinzeyTel: +1 617 835 9304Chris.Brinzey@westwicke.com ________ 1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings. ANNEX 1 ANNEX 2 Attachments OXUR Transparency Notification (NL) 2023.2.8.FINAL OXUR Transparency Notification (EN) 2023.2.8.FINAL

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group (“Negma”) has by notice to Mendus requested the conversion of convertible bonds that have been issued to Negma in accordance with the financing agreement announced by Mendus through press releases on 26 August and 26 October 2022. Negma has requested conversion of five (5) convertible bonds issued on 3 January 2023, corresponding to SEK 125,000 of the convertible loan amounting to a total of SEK 12,850,000, into 60,386 shares. Upon registration at the Swedish Companies Registration Office, Mendus’ total share capital will amount to SEK 9,991,646.75 and the total number of shares and votes will amount to 199 832 935. The conversion price per share is SEK 2.07, equivalent to 92% of the lowest closing volume weighted average share price (VWAP) of the 10 consecutive trading days preceding the issuance of conversion request by Negma. For further information regarding the convertible bonds issued on 3 January 2023, please refer to the press release published on 5 January 2023. Please refer to the section “Convertible Bonds” of the Investors page at Mendus’ website for a summary of all outstanding convertible bonds and issued shares upon conversion in regard to the financing agreement with Negma. FOR MORE INFORMATION, PLEASE CONTACT:Erik Manting Chief Executive Officer E-mail: ir@mendus.com INVESTOR RELATIONSCorey Davis LifeSci Advisors, LLC Telephone: + 1 212-915-2577 E-mail: cdavis@lifesciadvisors.com MEDIA RELATIONSMario Brkulj Valency Communications Telephone: +49 160 9352 9951 E-mail: mbrkulj@valencycomms.eu ABOUT MENDUS AB (PUBL) Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/ Attachment 230208_Mendus_Negma_5th_Conversion_ENG

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group (“Negma”) has by notice to Mendus requested the conversion of convertible bonds that have been issued to Negma in accordance with the financing agreement announced by Mendus through press releases on 26 August and 26 October 2022. Negma has requested conversion of two (2) convertible bonds issued on 3 January 2023, corresponding to SEK 50,000 of the convertible loan amounting to a total of SEK 13,700,000, into 20,325 shares. Upon registration at the Swedish Companies Registration Office, Mendus’ total share capital will amount to SEK 9,971,046.20 and the total number of shares and votes will amount to 199,420,924. The conversion price per share is SEK 2.46, equivalent to 92% of the second lowest closing volume weighted average share price (VWAP) of the 10 consecutive trading days preceding the issuance of conversion request by Negma. For further information regarding the convertible bonds issued on 3 January 2023, please refer to the press release published on 5 January 2023. Please refer to the section “Convertible Bonds” of the Investors page at Mendus’ website for a summary of all outstanding convertible bonds and issued shares upon conversion in regard to the financing agreement with Negma. FOR MORE INFORMATION, PLEASE CONTACT:Erik Manting Chief Executive Officer E-mail: ir@mendus.com INVESTOR RELATIONSCorey Davis LifeSci Advisors, LLC Telephone: + 1 212-915-2577 E-mail: cdavis@lifesciadvisors.com MEDIA RELATIONSMario Brkulj Valency Communications Telephone: +49 160 9352 9951 E-mail: mbrkulj@valencycomms.eu ABOUT MENDUS AB (PUBL) Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/ Attachment 230130_Mendus_Negma_1st_Tranche_Conversion_ENG